These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36736060)

  • 21. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
    Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M
    Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy.
    Valette CA; Filleron T; Debieuvre D; Lena H; Pérol M; Chouaid C; Simon G; Quantin X; Girard N
    Respir Med Res; 2023 Nov; 84():101012. PubMed ID: 37307617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Genetic variation in DNA repair gene RAD52 is associated with the response to platinum-based chemotherapy in SCLC patients].
    Li HM; Yuan P; Yu DK; Ma F; Tan WW; Feng T; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2016 Jul; 38(7):504-9. PubMed ID: 27531263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Timing of thoracic radiotherapy in limited stage small cell lung cancer: results of early versus late irradiation from a single institution in Turkey.
    Bayman E; Etiz D; Akcay M; Ak G
    Asian Pac J Cancer Prev; 2014; 15(15):6263-7. PubMed ID: 25124609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
    Kim SH; Jo EJ; Mok J; Lee K; Kim KU; Park HK; Lee MK; Eom JS; Kim MH
    Korean J Intern Med; 2023 Mar; 38(2):218-225. PubMed ID: 36800677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
    Steffens CC; Elender C; Hutzschenreuter U; Dille S; Binninger A; Spring L; Jänicke M; Marschner N;
    Lung Cancer; 2019 Apr; 130():216-225. PubMed ID: 30885347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
    Sanborn RE; Patel JD; Masters GA; Jayaram N; Stephens A; Guarino M; Misleh J; Wu J; Hanna N
    Cancer; 2017 Jan; 123(2):303-311. PubMed ID: 27583688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
    Mathieu L; Shah S; Pai-Scherf L; Larkins E; Vallejo J; Li X; Rodriguez L; Mishra-Kalyani P; Goldberg KB; Kluetz PG; Theoret MR; Beaver JA; Pazdur R; Singh H
    Oncologist; 2021 May; 26(5):433-438. PubMed ID: 33687763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
    Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ; Belani CP; Khuri FR; Ramalingam SS
    JAMA Oncol; 2017 Aug; 3(8):1120-1129. PubMed ID: 27978552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients.
    Hirsch FR; Osterlind K; Jeppesen N; Dombernowsky P; Ingeberg S; Sorensen PG; Kristensen C; Hansen HH
    Ann Oncol; 2001 May; 12(5):647-53. PubMed ID: 11432623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.
    Debieuvre D; Dayen C; Dixmier A; Pau D; Sibley-Revelat A; Greenwood W; Gally S; Falchero L
    Lung Cancer; 2022 Feb; 164():1-7. PubMed ID: 34954472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
    Kubo S; Kobayashi N; Matsumoto H; Somekawa K; Kaneko A; Hashimoto H; Teranishi S; Watanabe K; Horita N; Hara Y; Kudo M; Kaneko T
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17419-17426. PubMed ID: 37878090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65 years of age with stage III non-small cell lung cancer.
    Ezer N; Smith CB; Galsky MD; Mhango G; Gu F; Gomez J; Strauss GM; Wisnivesky J
    Radiother Oncol; 2014 Aug; 112(2):272-8. PubMed ID: 25150635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
    Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
    Santana-Davila R; Szabo A; Arce-Lara C; Williams CD; Kelley MJ; Whittle J
    J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
    Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
    Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.